

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 478-2012
FACSIMILE: (512) 536-5598

RECEIVED
JUN 13 2002
TECH CENTER 1600/2900

June 6, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 6, 2002	
Date	
	Gina N. Shishima

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/074,596 entitled "MODIFIED PROTEINS, DESIGNER TOXINS, AND METHODS OF MAKING THEREOF" by Michael G. Rosenblum and Lawrence Cheung*
Our Reference: CLFR:007US

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A6, B1, C1-C39).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201454/GNS.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Gina N. Shishima
Reg. No. 45,104

RECEIVED
JUL 01 2002
TECH CENTER 1600/2900

GNS/cmb
Encl.: as noted

25171520.1

PATENT

RECEIVED

JUN 13 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Michael G. Rosenblum
Lawrence Cheung

Serial No.: 10/074,596

Filed: February 12, 2002


For: MODIFIED PROTEINS, DESIGNER
TOXINS, AND METHODS OF MAKING
THEREOF



Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: CLRF:007US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 6, 2002	
Date	
	Gina N. Sotshima

RECEIVED

JUL 01 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201454/GNS.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 6, 2002

Form PTO-1449 (modified)	Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Michael G. Rosenblum Lawrence Cheung	
	Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1

TECH CENTER 1600/2900

JUN 13 2002

RECEIVED

U.S. Patent Documents							
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,962,188	10/9/90	Frankel	530	389	9/30/86
	A2	5,359,046	10/25/94	Capon <i>et al.</i>	536	23.4	12/9/92
	A3	5,631,348	5/20/97	Rosenblum <i>et al.</i>	530	370	6/6/94
	A4	5,837,491	11/17/98	Better <i>et al.</i>	435	69.1	5/12/94
	A5	6,084,073	7/4/00	Piatak, Jr.	530	370	6/5/95
	A6	6,099,842	8/8/00	Pastan <i>et al.</i>	424	183.1	12/3/90

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 89/00999	2/9/89	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Alfthan <i>et al.</i> , "Properties of single-chain antibody containing different linker peptides," <i>Protein Engineering</i> ; 8:725-731, 1995.
	C2	Berkower, "The promise and pitfalls of monoclonal antibody therapeutics," <i>Current Opinion in Biotechnology</i> , 7:622-628, 1996.
	C3	Bird <i>et al.</i> , "Single-chain antigen-binding proteins," <i>Science</i> ; 242:423-426, 1988.
	C4	GenBank Accession Number L12243.
	C5	Kim and Weaver, "Construction of a recombinant expression plasmid encoding a staphylococcal protein A-ricin A fusion protein," <i>Gene</i> ; 68:315-321, 1988.
	C6	Kipriyanov <i>et al.</i> , "Recombinant single-chain Fv fragments carrying c-terminal cysteine residues: production of bivalent and biotinylated miniantibodies," <i>Molecular Immunology</i> , 31:1047-1058, 1994.

25142374.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

TECH CENTER 1600/2900

JUL 01 2002

RECEIVED

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael G. Rosenblum Lawrence Cheung	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Koizumi <i>et al.</i> , "Immunoscintigraphy and pharmacokinetics of indium-111-labeled ZME-018 monoclonal antibody in patients with malignant melanoma," <i>Japanese J of Cancer Res</i> , 79:97-981, 1988.
	C8	Kudlicki <i>et al.</i> , "Elongation and folding of nascent ricin chains as peptidyl-rRNA on ribosomes: the effect of amino acid deletions on these processes," <i>J. Mol. Biol.</i> , 252:203-212, 1995.
	C9	Kurucz <i>et al.</i> , "A bacterial expressed single-chain Fv construct from the 2B4 T-cell receptor," <i>Proc Natl Acad Sci USA</i> ; 90: 3830-3834, 1993.
	C10	Levy <i>et al.</i> , "Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells," <i>Nat. Biotechnol.</i> , 14:610-614, 1996.
	C11	Macey <i>et al.</i> , "Uptake of Indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma," <i>Am J of Physiologic Imaging</i> ; 3:1-6, 1988.
	C12	Mazurier <i>et al.</i> , "Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein," <i>Gene Ther.</i> , 5:556-562, 1998.
	C13	McCartney <i>et al.</i> , "Engineering disulfide-linked single-chain Fv dimers [(sFv') ₂] with improved solution and targeting properties: anti-digoxin 26-10 (sFv') ₂ and anti-c-erbB-2 741F8 (sFv') ₂ made by protein folding and bonded through C-terminal cysteinyl peptides," <i>Protein Engineering</i> ; 8:301-314, 1994.
	C14	Morris and Wool, "Determination by systematic deletion of the amino acids essential for catlysis by ricin A chain," <i>Proc. Natl. Acad. Sci. USA</i> , 89:4869-4873, 1992.
	C15	Mujoo <i>et al.</i> , "Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin," <i>Cancer Immunology, Immunotherapy</i> ; 40:339-345, 1995.
	C16	Muldoon <i>et al.</i> , "Tracking and quantitation of retroviral-mediated transfer using a completely humanized, red-shifted green fluorescent protein gene," <i>Biotechniques</i> , 22:162-167, 1997.
	C17	Munishkin and Wool, "Systematic deletion analysis of ricin A-chain function," <i>J Biol. Chem.</i> , 270:30581-30587, 1995.
	C18	Nechushtan <i>et al.</i> , "Conformation of the Bax C-terminus regulates subcellular location and cell death," <i>EMBO Journal</i> , 18:2330-2341, 1999.

25142374.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED
JUN 13 2002
JUL 01 2002

TECH CENTER 1600/2900
TECH CENTER 1600/2900

Form PTO-1449 (modified)		Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael G. Rosenblum Lawrence Cheung	
		Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	O'Boyle <i>et al.</i> , "Potentiation of antiproliferative effects of monoclonal antibody LYm-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with γ -interferon and tumor necrosis factor," <i>Journal of Immunotherapy</i> ; 18:221-230, 1995.
	C20	O'Hare <i>et al.</i> , "Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence," <i>FEBS Lett.</i> ; 273:200-204, 1990.
	C21	Owens and Young, "The genetic engineering of monoclonal antibodies," <i>Journal of Immunological Methods</i> ; 168:149-165, 1994.
	C22	Panchagnula <i>et al.</i> , "Monoclonal antibodies in drug targeting," <i>Journal of Clinical Pharmacy & Therapeutics</i> , 22:7-19, 1997.
	C23	Panchal, "Novel therapeutic strategies to selectively kill cancer cells," <i>Biochemical Pharmacology</i> , 55:247-252, 1998.
	C24	Peterson and Krohn, "Mapping of B cell epitopes on steroid 17 α -hydroxylase, and autoantigen in autoimmune polyglandular syndrome type I," <i>Clin. Exp. Immunol.</i> , 98:104-109, 1994.
	C25	Porter, "Human immune response to recombinant human proteins," <i>J. Pharmaceutical Sciences</i> , 90:1-11, 2001.
	C26	Pullyblank and Monson, "Monoclonal antibody treatment of colorectal cancer," <i>British Journal of Surgery</i> ; 84:1511-1517, 1997.
	C27	Roselli <i>et al.</i> , "Clinical value of radiolabeled monoclonal antibodies in the management of carcinoma patients," <i>In Vivo</i> , 7:615-622, 1993.
	C28	Rosenblum <i>et al.</i> , "Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin," <i>Cancer Chemotherapy and Pharmacology</i> ; 44:343-348, 1999.
	C29	Rosenblum <i>et al.</i> , "A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin," <i>Molecular Biotherapy</i> ; 3:6-13, 1991.
	C30	Rosenblum <i>et al.</i> , "Amino acid sequence analysis, gene construction, cloning and expression of gelonin, a toxin derived from <i>Gelonium multiflorum</i> ," <i>Journal of Interferon & Cytokine Research</i> , 15: 547-555, 1995.

25142374.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

JUN 13 2002

RECEIVED

JUL 01 2002

TECH CENTER 1600/2900

RECEIVED

JUN 13 2002

TECH CENTER 1600/2900

Form PTO-1449 (modified)	Atty. Docket No. CLFR:007US	Serial No. 10/074,596
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Michael G. Rosenblum Lawrence Cheung	
	Filing Date: February 12, 2002	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Des.	Ref. Des.	Citation
	C31	Rosenblum <i>et al.</i> , "Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in Xenograft models," <i>Clin Cancer Res</i> ; 5:865-874, 1999.
	C32	Rowlinson-Busza <i>et al.</i> , "Target delivery of biologic and other antineoplastic agents," <i>Current Opinion in Oncology</i> , 4:1142-1148, 1992.
	C33	Stirpe <i>et al.</i> , "Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells," <i>A Journal of Biological Chemistry</i> , 255:6947-6953, 1980.
	C34	Wahl <i>et al.</i> , "Experimental radioimmunotherapy," <i>Cancer</i> , 73:989-992, 1994.
	C35	Wels <i>et al.</i> , "Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor," <i>Journal of Steroid Biochemistry & Molecular Biology</i> , 43:1-7, 1992.
	C36	Williams <i>et al.</i> , "Targeting and therapy of human glioma xenografts in vivo utilizing radiolabeled antibodies," <i>Cancer Res</i> , 50:974s-979s, 1990.
	C37	Wool <i>et al.</i> , "Structure and evolution of mammalian ribosomal proteins," <i>Biochem Cell Biol.</i> , 73:933-947, 1995
	C38	Worn and Pluckthun, "Mutual stabilization of V _L and V _H in single-chain antibody fragments, investigated with mutants engineered for stability," <i>Biochemistry</i> ; 37:13120-13127, 1998.
	C39	Xu <i>et al.</i> , "Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice," <i>Leukemia</i> , 10:321-326, 1996.

25142374.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

TECH CENTER 1600/2900

JUL 01 2002

RECEIVED

